BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18341668)

  • 21. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring.
    Nath CE; Shaw PJ
    Curr Clin Pharmacol; 2007 Jan; 2(1):75-91. PubMed ID: 18690856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2005 Mar; 59(3):314-24. PubMed ID: 15752378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
    Cremers S; Schoemaker R; Bredius R; den Hartigh J; Ball L; Twiss I; Vermeij P; Vossen J
    Br J Clin Pharmacol; 2002 Apr; 53(4):386-9. PubMed ID: 11966670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
    Vassal G; Koscielny S; Challine D; Valteau-Couanet D; Boland I; Deroussent A; Lemerle J; Gouyette A; Hartmann O
    Cancer Chemother Pharmacol; 1996; 37(3):247-53. PubMed ID: 8529285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
    Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal busulphan: bioavailability and effect on bone marrow in mice.
    Hassan Z; Nilsson C; Hassan M
    Bone Marrow Transplant; 1998 Nov; 22(9):913-8. PubMed ID: 9827821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
    Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
    Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
    Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
    Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE
    Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective appraisal of busulfan dose adjustment in children.
    Dupuis LL; Najdova M; Saunders EF
    Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
    Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
    Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.
    Diestelhorst C; Boos J; McCune JS; Hempel G
    Eur J Clin Pharmacol; 2014 Jul; 70(7):839-47. PubMed ID: 24810613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
    Lawson R; Paterson L; Fraser CJ; Hennig S
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ; Nath C; Berry A; Earl JW
    Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.